classes. These phenotypes differed in their disease severity including symptoms and quality of life. Physicians in real-life practice prescribed medication regardless of the phenotype and severity, with the exception of patients with ocular symptoms. Prescribed treatments were comparable in hypothesis-and data-driven analyses. The prevalence of uncontrolled patients during treatment was similar in the 4 clusters, but was significantly different according to the ARIA classes. Conclusion: Cluster analysis using demographic and clinical parameters only does not appear to add relevant information for disease stratification in allergic rhinitis.
The hypothesis-driven stratification of patients with allergic rhinitis (AR) generally embeds clinical outcomes, disease severity or control [3] . No objective parameters or biomarkers have been identified to stratify patients with AR. ARIA (Allergic Rhinitis and Its Impact on Asthma), the most widely used guideline, includes symptom severity, quality of life (QoL) and duration of disease, and proposes a simple stratification of AR applicable in daily practice [4] . This classification can be used in treated or untreated patients [5] . The visual analogue scale (VAS) has been used in many studies [6] [7] [8] [9] and was found to be clinically relevant for stratifying patients and assessing treatment efficacy [3, 5, 10, 11] . Patients who fail to respond to pharmacologic treatment are classified as SCUAD (severe chronic upper airway disease) [12, 13] .
A novel phenotypic characterization for allergic diseases appears to be needed to distinguish groups of patients presenting homogeneous clinical, prognostic characteristics and responses to treatments. The identification of phenotypes could lead to an improved management and AR control. Popular epidemiologic approaches, such as the unsupervised statistical techniques, have recently emerged to meet these needs. These approaches consist of applying unsupervised statistical methods to a population with a wide distribution of related symptoms, and then identifying the possible underlying phenotypes. Each of these phenotypes should be as homogeneous as possible and have as little overlap as possible with each of the other phenotypes. Phenotypes are not known a priori, and there are no predefined views about them. There are different types of clustering approaches such as hierarchical, partitioning and model-based clustering [14] or network analysis [15] . Many studies in asthma and allergic diseases have used various clustering methods to stratify patients [16] [17] [18] [19] [20] [21] [22] . One of the recommended methods is Ward's hierarchical cluster analysis [23, 24] .
To our knowledge, these data-driven approaches have not been published in a patient population suffering from AR. The validation of the observed phenotypes is a critical and yet unresolved issue that may be performed by testing the predictive performance of clusters in a clinical trial. The clinical benefit of using cluster analysis versus a hypothesis-driven approach has not been established. Moreover, it may be difficult to apply a cluster analysis in clinical practice.
A French observational prospective multicenter study (EVEIL: Echelle visuelle analogique dans la rhinite allergique) was carried out on 990 patients consulting general practitioners (GPs) for AR and treated as per clinical practice. In this study, changes in symptom scores, VAS and QoL were measured at baseline and after 14 days of treatment [25] . The study involved a careful evaluation of demographic and clinical characteristics [26] and was suitable for cluster analysis. We performed a post hoc analysis using the dataset of the EVEIL study to identify clusters of patients with AR using Ward's hierarchical method, and to define their clinical relevance at baseline and after 14 days of treatment. The cluster approach was compared to ARIA, a hypothesis-driven approach largely used in clinical practice [4] .
Methods

Study Design
The data were obtained from a multicenter prospective observational study carried out throughout France (EVEIL). The protocol and descriptive characteristics are described elsewhere [25, 26] . The main objective of this post hoc analysis was to identify clusters using Ward's method. Secondary objectives were (1) to compare VAS, QoL, total symptom scores (TSS) and ARIA classes at baseline in the identified clusters, (2) to define the treatments received by the patients and their efficacy according to the clusters, (3) to compare the differences in patient stratification and prediction of treatment benefits by using cluster analysis (data driven), ARIA guidelines (hypothesis driven) or the levels of VAS at baseline. The percentage of uncontrolled patients (SCUAD) was also assessed in each cluster or ARIA class.
GPs were randomly selected by means of geographic stratification. Physicians completed a questionnaire on the consultation day which included sociodemographic data, diagnostic history, rhinitis symptoms, concomitant diagnosed pathologies and treatment prescription. The management of AR was at the physicians' discretion and patients were reviewed after 14 days of treatment.
Patients
Patients were included in the study after oral informed consent was obtained and after approval of the protocol by the Ethics Committee of Montpellier, France. Patients were enrolled for 1 year (February 2010 to January 2011) and were selected from all regions of France in order to rule out any geographic or seasonal parameter. All patients fulfilled the following inclusion criteria: over 18 years of age with a diagnosis of AR and presenting clinical symptoms of AR on the consultation day.
Outcome Measures
Individual nasal and ocular symptoms, TSS, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and VAS were assessed by the patients on the consultation day and 14 days later (online suppl. S1; for all online suppl. material, see www.karger.com/ doi/10.1159/000381339).
Cluster Analysis Variable Reduction
The whole dataset provided many variables that required reduction in number before performance of a cluster analysis. The selection of input variables was processed by excluding irrelevant 233 variables, variables with many missing data (>100 missing data) and variables with text format (e.g. 'others'; online suppl. fig. S1 ). For the current analysis, two variables were considered as irrelevant: (1) the physician who diagnosed the disease and (2) the information about the next follow-up consultation (the date). After reduction, relationships between the 18 variables were studied by cluster analysis, using the VARCLUS (variable cluster) procedure [27, 28] . This procedure, which organizes a set of numeric variables into hierarchical clusters, can be used to examine redundancy between variables. Therefore, one single representative variable was chosen from each cluster and the other variables were discarded. It can be noted that the smallest value of the 1-R 2 ratio was used to guide the selection. A summary of this procedure is presented in online supplementary table S1.
Identification of AR Phenotypes
Ward's minimum-variance hierarchical clustering was performed to identify AR phenotypes. In this method, the agglomerative approach was based on the quantitative measures of similarity procedure (minimum within cluster sum of square). Subsequently, patients in the same cluster were more similar to each other than those in different clusters. The algorithm then proceeded by merging the two most similar clusters until there was only one single cluster. We used pseudo-F statistics to determine the optimal number of clusters in the data.
Biases
To reduce biases, we performed an unsupervised clustering using a statistical algorithm to select classes inherent to the data. Therefore, the statistical method used allows unbiased analyses that are not based on any a priori assumptions. One of the potential biases would be the population included in the algorithm. Only 825 out of the 990 recruited patients were included in the algorithm. Patients with incomplete datasets were excluded from the analyses, which requested complete data. Clustering was exclusively based on clinical variables and questionnaires -no biological variables or biomarker data were available. Our approach was appropriate for the identification of clusters in clinical practice. It is possible that inclusion of other variables (e.g. biomarkers) may have improved the ability to identify phenotypes.
Statistical Analysis
Descriptive statistics were supplied according to the variable nature. For quantitative variables, the number of nonmissing observations, arithmetic mean, median, standard deviation, minimum and maximum were presented. For qualitative variables, the number of nonmissing observations, frequency and percentage were presented.
The clusters were compared to identify which of the input variables were significantly different between clusters. Comparisons were provided using ANOVA or a Kruskal-Wallis test for quantitative variables and Pearson's χ 2 or Fischer's exact test, as appropriate, for qualitative variables.
The description of real-life management and outcomes was performed on the identified clusters using descriptive statistics. The described variables included VAS, TSS and RQLQ outcomes before and after treatment.
Logistic regression was used to identify factors associated with uncontrolled SCUAD AR. Patients with SCUAD were defined pre hoc as those with a VAS level ≥ 50 mm and/or presence of ocular symptoms (ranked ≥ 2) at the end of the 2-week treatment [13] . The variables significant at the 0.2 level in bivariate analyses were entered into this multivariate logistic regression.
Results
Demographic Characteristics
A total of 191 GPs throughout France participated in the EVEIL study and 161 enrolled at least 1 patient. 990 consecutive patients consulting for AR were included. Among the 990 patients, 825 (83%) were included in this post hoc analysis (online suppl. fig. S2 ). Patients with missing data identified during the VARCLUS procedure were excluded. The baseline characteristics of the patients are described in online supplementary S2.
Cluster Description
The classification of 825 patients with AR using agglomerative cluster analysis generated a dendrogram (online suppl. fig. S3 ). As is shown in the dendrogram, cluster 1 was differentiated mainly by the treatments received prior to the consultation day such as oral/nasal antihistamine, corticoids, ocular antihistamine and OTC. Cluster 2 was characterized by the severity of the disease assessed using the ARIA classes, VAS and TSS6 at inclusion. Cluster 3 was characterized by the presence of comorbidities such as a documented allergy, presence of concomitant skin or respiratory disease and the use of antileukotriene (antiasthmatic agent), and cluster 4 identified patient age and duration of diagnostics.
Four clusters classified by number of subjects per cluster (1-4) were identified from mild to severe phenotype ( fig. 1 ). Two extreme phenotypes were identified: cluster 2 was the mildest phenotype, whereas cluster 4 was the most severe. Significant differences in age, symptoms and severity were found among the four clusters. Baseline sociodemographics and clinical characteristics of the 825 patients according to these four clusters are presented in table 1 . Symptoms and disease burden at baseline are presented in table 2 . Clusters 1 and 3 included patients with moderate-tosevere phenotypes. However, cluster 1 was more severe than cluster 3, with slightly more patients suffering from severe/moderate persistent AR. Compared with patients in cluster 3, patients in cluster 1 had the worst QoL and symptoms, and the greatest disease burden. Cluster 3 was the only cluster where the majority of patients were male.
Cluster 2 consisted mainly of women with a median age of 40 years. The median age of AR onset was 5 years.
The patients in this cluster were mainly classified as having mild intermittent AR. They had less concomitant comorbidities, including skin or respiratory conditions, than the other clusters. They experienced significantly fewer symptoms than the other clusters. Cluster 2 patients had a mild impairment in QoL, with a mild symptom score and low level of disease burden.
Cluster 4 consisted mainly of young women: 59% were female patients with a median age of 36 years. The median age of AR onset was 10 years, the oldest between the clusters. The majority of patients in cluster 4 presented with severe/moderate persistent AR (75%) and with a diagnosed allergy (60%). Cluster 4 patients had a significantly impaired QoL with a severe symptom score and high level of disease burden.
Differences in some allergens were observed between clusters, particularly for tree pollen, grasses and weeds ( table 1 ) .
On the consultation day, 73% of patients were receiving medications for AR regardless of the cluster or disease severity. Treatment of AR received prior to the GP consultation was not a confounding variable among the clusters.
Real-Life Management and Medication Prescribed during the Consultation
During the consultation, all patients received a prescription for medications. 73% received an H 1 -antihistamine (oral or nasal) associated with corticosteroids (65% nasal) (online suppl. table S2). No significant differences were found in the prescription of any treatment between clusters. However, ocular H 1 -antihistamines and antileukotrienes were more frequently prescribed in clusters 1 and 4 ( table 3 a).
Clinical Outcomes in Data-Driven Clusters at the End of Treatment
A significant clinical improvement was observed in all clusters 14 days after consultation with a reduction of TSS, RQLQ and VAS ( table 4 a). Although there were differences between clusters, they were relatively small.
Twenty-one percent of the patients were characterized as having SCUAD at day 14. A nonsignificant difference was found between the clusters, although clusters 4 (30.1%) and 1 (24.4%) included more SCUAD patients than clusters 2 (19.4%) and 3 (15.4%). 
Clinical Outcomes in Hypothesis-Driven ARIA Classes at the End of Treatment
Patients classified by ARIA at baseline were prescribed a similar treatment in the 4 classes except for ocular H 1 -antihistamines that were prescribed more often in patients with ocular symptoms ( table 3 b). The percentage of SCUAD patients after 14 days of treatment was significantly different depending on ARIA classes, ranging from 9.9% in mild intermittent rhinitis to 27.9% in moderate/severe persistent rhinitis. Similarly, TSS6, RQLQ and VAS levels after treatment increased significantly from mild intermittent rhinitis to mild persistent, moderate-severe intermittent and moderate-severe persistent rhinitis ( table 4 b). Values are given as means ± SD or n (%). NC = Not computed; COPD = chronic obstructive pulmonary disease. 1 Sinusitis included the acute and chronic forms. Sinusitis and nasal polyps were reported at the physician's discretion. No definitions were provided in the protocol.
Predictive Factors for SCUAD
A bivariate model followed by multivariate analysis was used to determine the predictive factors of SCUAD in AR patients ( table 5 ). This analysis showed that presence of fever, other respiratory disease, ocular symptoms or the use of ocular H 1 -antihistamines are predictive factors of SCUAD. On the other hand, mild intermittent AR, presence of nasal obstruction and pruritus were less associated with SCUAD. Clusters were not associated with SCUAD.
Discussion
A data-driven analysis showed that patients can be clustered into 4 phenotypes which partly follow ARIA, a hypothesis-driven analysis. These phenotypes differed in their disease severity including symptoms and QoL. Physicians in real-life practice prescribe medication regardless of the phenotype and severity, with the exception of patients with ocular symptoms. Prescribed treatments were comparable in hypothesis-and datadriven analysis. The prevalence of uncontrolled patients during treatment (SCUAD) was similar in the 4 clusters but was significantly different according to ARIA classes.
Limitations
This post hoc study was not initially designed to define clusters, but clinical parameters would not have differed largely if the study had been planned for cluster analysis.
This analysis is an 'unsupervised analysis clustering'. Unsupervised clustering are types of algorithms that try to find correlations between parameters without any external inputs other than the raw data. Only the algorithm decides to group datasets into clusters that share common properties. We chose this analysis since it was a post hoc analysis; the primary objective of the study was to validate the VAS tool in AR. As it was an observational study, there were many missing data and collected parameters were not clinical or standardized. This was the reason why we decided to do an exploratory 'unsupervised' analysis. The selection of criteria is crucial for any cluster analysis. A large number of clinical outcomes were used, including symptoms, QOL and ARIA classes. Biologic criteria were not included, but (1) it has not been shown that blood eosinophils are highly increased in AR in contradistinction to asthma [16, 18] , (2) the presence of an allergic sensitization did not significantly change the cluster analysis and (3) clusters are quite well differentiated in the present study, suggesting that other criteria may not have a very large impact. In this analysis, we followed methods used elsewhere for asthma [29] . Ward's mini- 237 mum-variance hierarchical clustering method was performed using an agglomerative approach and Ward's linkage (dendrogram). Stepwise discriminant analysis was performed to identify the 18 discriminant variables. Using the VARCLUS cluster analysis in SAS, the variables were classified. When the patterns of response to two variables were similar for most patients, these variables were grouped and the variable with the smallest ration 1-R 2 in the group was selected. Six variables were then selected and considered as discriminant (online suppl. table S1).
EVEIL is a cross-sectional study and clusters can also be defined in longitudinal studies [19, 21] . In children, trajectories of allergic diseases or asthma show that longitudinal-based clusters are of interest [30, 31] . In adults with AR, differences in disease prevalence exist in longitudinal studies and patients with AR may develop asthma [32] . However, these changes appear more limited than in children and the transition from AR to AR and asthma is not very common. However, more studies are needed to determine the impact of time on cluster analyses.
It might have been useful to perform several types of cluster analyses since there are different types of approaches like hierarchical, partitioning and model-based clustering [14] or network analysis [15] . However, except for latent class analysis, results are expected to be similar.
It may be considered that the cohort of patients is insufficiently defined and that not all of the criteria have been used (e.g. serum IgE, eosinophils). However, the strength of the study was studying patients who were attending primary care using the criteria GPs use. Not all patients had a diagnosis of allergy, but they are represen- tative of the patient population seen by GPs in France. Therefore, some patients may have presented with non-AR, but clusters were similar in patients with or without a diagnosis of allergy. Allergy was defined using broad criteria including skin tests and serum allergen-specific IgE. However, since the difference between in vivo and in vitro tests is not clear [33] , it appears that the diagnosis of allergy is acceptable and representative of daily practice in primary care. However, the characterization of patients is not as precise as in specialist clinics. Previous studies carried out by our group found that the ARIA classification performed in primary care or specialist practices in France was comparable [34, 35] . There were no major differences in phenotypes between patients with an allergy diagnosis and those without [34] . Moreover, the clinical results of the study previously published strongly suggest that the classification of patients was appropriate [26, 36] . Clusters may differ from the general population since patients usually consult for moderate-to-severe AR [34] . Moreover, it is possible that clusters carried out in specialist practices may differ, but this can only be studied in a specifically designed experiment.
This study was carried out in France but results may have been different if carried out in other countries.
Strengths
The present study is a real-life study without any exclusion criteria and is representative of the French patients seen by GPs. It has strengths including: (1) a sufficient power to detect changes, (2) a clinical validation of the cluster analysis during a follow-up of 14 days, this duration of treatment being sufficient to detect changes in AR [37] [38] [39] , and (3) a comparison of clinical outcomes during treatment with the most widely used classification Values are given as means ± SD or n (%). 1 Defined by SCUAD. of patients (ARIA) [40] . Another strength of the study was that complexity in phenotype analysis may not be needed to understand AR in clinical practice. However, this finding should be replicated. To the best of our knowledge, this is the first study to assess cluster analysis in rhinitis.
Generalizability
In the present study, it was found that GPs treat all patients similarly whatever the cluster or ARIA class, confirming other European cohorts [41, 42] . Most patients received a combination of oral H 1 -antihistamines and intranasal corticosteroids. Physicians in real-life practice prescribe medication regardless of the phenotype and severity [41, 43] . This is possibly because most patients present severe symptoms despite a treatment. The treatment prescribed is, however, at variance from guidelines.
Integrated care pathways (ICPs) [44] promote the translation of guidelines into local protocols and their subsequent application to clinical practice. ICPs differ from practice guidelines and need to record variations from planned care [45] . Any alteration to the practice identified within this ICP must be noted as a variance [46] . In the present study, variance was found for the treatment of patients by primary care physicians whereas the ARIA classification was reinforced. This variance analysis should be used to propose novel ICPs since, for the majority of patients, the practice differs from the guideline.
Surprisingly, the hypothesis-driven ARIA classification was more predictive of SCUAD than the data-driven cluster analysis. Patients with mild intermittent rhinitis were unlikely to be SCUAD patients. The data-driven phenotyping of the present study is unlikely to improve the management of patients with AR.
The present study questions whether data-driven clusters are needed in the management of AR in clinical practice. A recent study in chronic obstructive pulmonary disease did not detect any further interest, showing that the two clusters predicting mortality fit quite well with those that have been known for decades [47] . It is therefore possible that in relatively well-defined diseases, cluster analysis is not necessary to stratify patients. Moreover, the phenotypes resulting from cluster analysis should be validated prospectively with regards to the patient's outcomes. However, in the present study, clusters depended mainly on the symptoms and scores. This is probably due to the limited variables collected at baseline and to the study design. More studies are needed, but, to date, the clinical evaluation of patients appears to be sufficient for predicting uncontrolled patients during treatment and managing AR.
In conclusion, although an insufficient number of primary care physicians stratify patients in terms of severity, clinical parameters readily available in practitioners' offices are helpful in assessing the response to treatment in AR: cluster analysis in AR does not appear to have a relevant impact on disease stratification and clinical outcomes after treatment.
